VALINK THERAPEUTICS LTD
Company number 13077801 · Monitor this company
Free AI analysis
Have an AI read this company's filings and write an assessment — financial health, risks, and what the numbers say.
Shareholders' funds
£10,273,484
Balance sheet as at 2025-12-31
Overview
- Company type
- Private Limited Company
- Incorporated
- 2020-12-11
- Employees
- 16 (2025 accounts · was 13 in 2024)
- Registered office
- Imperial Translation & Innovation Hub, 84 Wood Lane, London, England, W12 0BZ.
- Postcode
- W12 0BZ.
- Capital
- 103 GBP
- Accounts category
- Total Exemption Full
Accounts
- Last made up to
- 2025-12-31
- Next due by
- 2027-09-30
- Financial year end
- 31 December
Confirmation statement
- Last statement dated
- 2025-12-10
- Next due by
- 2026-12-24
Nature of business (SIC)
- 72110 Research and experimental development on biotechnology
Officers 1 current · 2 resigned
Licensed visa sponsor
Licensed by the Home Office to sponsor worker visas: Skilled Worker (Worker (A rating)).
Matched by registered name to the register of licensed sponsors (Home Office, updated daily) — check the register itself before relying on it. Contains public sector information licensed under the Open Government Licence v3.0.
Contact details
- Website
- valinktherapeutics.com
Valink is developing a series of novel therapeutics that are more effective at attacking tumours, while sparing healthy tissue.
Previous company names
| Name | Date changed |
|---|---|
| LILIUMX LTD. | 2023-11-03 |
Among its peers
Top 5%
by shareholders' funds, of 141 similar companies in W
Among the biggest employers among its local peers (16 staff).
Trading since 2020.
No.6 of the largest research and experimental development on biotechnology companies in London →
Competitors London
This company ranks 6 among research and experimental development on biotechnology in London.
The class of 2020
41%
of the 596 companies in this sector incorporated in 2020 are still active today; 54% have since been dissolved.
A fact about the year, not a forecast for this company.